Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KitazatoTSE:368A +0.79%22 EBITDA Margin % is 57.47% as of Mar. 2026, which is 1% above its 10-year median of 56.89. GuruFocus rates TSE:368A with a GF Score™ of 22/100. Among 815 Medical Devices & Instruments companies, Kitazato ranks better than 98.65% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kitazato's EBITDA for the
six
months ended in Mar. 2026 was 円3,276 Mil. Kitazato's Revenue for the
six
months ended in Mar. 2026 was 円5,700 Mil. Therefore, Kitazato's EBITDA margin for the quarter that ended in Mar. 2026 was 57.47%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kitazato EBITDA Margin % Related Terms
Kitazato EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kitazato's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:368A vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Kitazato's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kitazato EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kitazato's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kitazato's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kitazato (TSE:368A) has a EBITDA Margin % of 57.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kitazato and its competitors. This is near median its historical median of 56.89. Over the past decade, Kitazato's EBITDA Margin % has ranged from 55.68 to 61.24. According to the industry distribution chart, Kitazato ranks #11 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 1.3%.
Is Kitazato's EBITDA Margin % too high?
Kitazato's current EBITDA Margin % of 57.47% is near median its 10-year median of 56.89. Over the past 10 years, this metric has ranged from a low of 55.68 to a high of 61.24. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Kitazato's value of 57.47% is 664.2% above this industry median. Based on the distribution chart, Kitazato ranks #11 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kitazato has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Kitazato's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Kitazato ranks #11 out of 815 companies for EBITDA Margin %. This places Kitazato in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.52. Kitazato's value of 57.47% is 664.2% above this benchmark. Historically, Kitazato's own EBITDA Margin % has ranged from 55.68 to 61.24 over the past decade. While the company's 10-year median is 56.89 vs. the industry median of 7.52, Kitazato has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kitazato's current EBITDA Margin % of 57.47% is 664.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kitazato and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kitazato's current EBITDA Margin % is 57.47%, which is near median its own 10-year median of 56.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kitazato stock overvalued right now?
Kitazato (TSE:368A) has a current EBITDA Margin % of 57.47%. The current EBITDA Margin % is 57.47%, which is near median its 10-year median of 56.89 and 664.2% above the Medical Devices & Instruments industry median of 7.52. Kitazato's overall GF Score™ is 22/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kitazato (TSE:368A), the current EBITDA Margin % is 57.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kitazato Corp is engaged in manufacture and sale of medical devices and related products for fertility treatment. Its products include Needles, Catheters and Cannulas, Vitrification Media and Equipments, Sperm Processing Medium/Tools, IVF Medium, etc.
22GF Score
Get the complete analysis for TSE:368A
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:368A has been successfully added to your 
